热门资讯> 正文

Teva长效抗精神病药Uzedy获得双相情感障碍的适应症

2025-10-11 04:29

The U.S. FDA has expanded the indication for Teva Pharmaceutical Industries' (NYSE:TEVA) long-acting atypical antipsychotic Uzedy (risperidone) as monotherapy or adjunctive therapy to lithium or valproate for maintenance treatment of bipolar I disorder.
Uzedy is given via subcutaneous injection once a month for the new indication. It was already used for schizophrenia.
Approval was based on the FDA's previous evaluation of prior risperidone formulations approved for bipolar disorder as well as two phase 3 studies for Uzedy for schizophrenia.

More on Teva Pharmaceutical

Teva Pharmaceutical: Turnaround Driven By Huge Pipeline Upside
Teva Pharmaceuticals: Pipeline Momentum Signals New Era For Investors
Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2025 Transcript
FDA introduces program to expedite review of domestic generic drugs
Bausch, Teva face lawsuit for delay in generic version of Xifaxan

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。